170 likes | 177 Vues
This presentation discusses the design of a surface plasmon resonance (SPR) biointerface for transmembrane proteins, specifically focusing on the Epidermal Growth Factor Receptor (EGFR). The experimental approach, results, and future work are outlined, highlighting the use of metals with free electrons and the application of SAMs and biotinylated surfaces. Key findings suggest effective immobilization of EGFR and preferential binding to cells overexpressing EGFR. Future steps include further interface design optimization and high-throughput screening using SPR imaging.
E N D
Designing an SPR biointerface for transmembrane proteins Heather Ferguson Matthew Linman, Dr. Quan “Jason” Cheng BRITE Research Presentation August 20, 2009
Background information SPR and EGFR Experimental approach Results Conclusions Future work Outline
Metals with free electrons Gold, silver P-polarized light at resonance angle excites electrons Angle at which photons couple with plasmons Plasmons are collective vibrations of electron gas Background - SPR
Experimental Setup for SPR Characteristic Sensorgram (2) Association (3) Equilibrium (4) Dissociation Cooper, M.A. Nat. Rev. Drug Discovery 2002, 1, 517
Membrane Proteins • Target of 60% of drugs • Epidermal Growth Factor (EGFR) • Overexpressed in epithelial cancers • Lung, ovary, breast, colon • 3 domains • Intracellular tyrosine kinase • lipophilictransmembrane • Extracellular ligand binding • Antibodies • Polyclonal: anti-EGFR TK • mAb: Erbitux® (cetuximab) • Provided by: Eureka Therapeutics Inc. Huang S., Invest New Drugs1999, 259-269
Methods – Protein Concentration Assay • Purify cells • Extract proteins • Bio-Rad Protein Assay kit • Colorimetric, similar to ELISA • Folin reagent + alkaline copper tartrate • UV/vis spectroscopy to measure absorbance • Use standards to make calibration curve (1.6 – 0.2 mg/ml) • Determined [EGFR] 4.06 mg/ml
Methods - SAM 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC) N-hydroxysulfosuccinimide (Sulfo-NHS) SH(CH2)10 COOH • Stable bond between sulfur and gold • Short hydrocarbon chain • Change functional groups Johanna Stettner, Institute of Solid State Physics, Graz University of Technology
Covalent Coupling mAb to SAM • mAb binding significantly stronger to EGFR cells than the control
SAM-Based Design on Polyclonal Ab • EGFR cells = 84.3 mdeg • Control = 62.9 mdeg • Control signal still large
EGFR in Tethered Bilayer Membrane • Small signal increase after injection of Anti-EGFR (2 µg/ml) • Co-injected PC vesicles along with cells • EGFR cells = 413 mdeg • Control cells = 352 mdeg • Tethered membrane provides space • Biologically relevant
Interface Design II: Biotinylation Biotin NHS • Biotin-Avidin bonds • Very strong (Ka = 1015 M-1 ) • orientation specific • Biotinylate TK antibody • Sulfo-NHS-LC-Biotin kit
Effect of Biotinylation Biotin BSA signal 3X greater than control
Complete Surface System • Biotin BSA, NeutrAvidin, biotin anti-EGFR, PC vesicles + cells (EGFR and control) • Ideally, the signal should be greater from the EGFR cells, and Erbitux should have a greater signal
Conclusions • Biotinylation procedure is effective. • Erbitux shows preferential binding to cells overexpressing EGFR compared to control cells. • Current method of combining EGFR and PC vesicles can be improved. • Lack of signal between EGFR cells in lipid membrane and Erbitux may indicate improper orientation within the membrane • Both SAMs and biotinylated surfaces show promise
Next Steps • Determine ideal membrane interface design for effective and functional EGFR immobilization for protein binding. • Try different lipid mixtures to more closely mimic natural membrane • Create an interface based on the calcinated chip (glassified layer on gold) for direct immobilization of the EGFR in a membrane. • Use mAb Erbitux once ideal interface design is determined • Apply best interface design to a microarray format for high-throughput screening with SPR imaging.
Acknowledgements Matt Linman and Dr. Cheng National Science Foundation Jun Wang and BRITE REU program
References • Hopkins, A. L.; Groom, C. R. Nat.Rev. Drug Discovery 2002, 1, 727–730. • Hubbard, S. R. Cancer Cell 2005, 7, 287-288. • Kim, Edward S., et al. Epidermal growth factor receptor biology. Current Opinion in Oncology2001, 13, 506-513. • Li, Shiqing; et al. Cancer Cell 2005, 7, 301-311. • Liedberg, B., I. Lundstrom, and E. Stenberg. 1993. Principles of biosensing with an extended coupling matrix and surface plasmon resonance. Sensors and Actuators B 11: 63-72. • Linman, M. J.; Culver S.P.; Cheng Q. Langmuir 2009, 25, 3075-3082. • Macher, Bruce A., Yen, Ten-Yang. Proteins at membrane surfaces – a review of approaches. Mol. Biosyst.2007, 3, 705-713.